Evidence map›Paper›PMID 27986853›Full record

ArticleNucleic acids research2017

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2.

Elad Elkayam, Rubina Parmar, Christopher R Brown, Jennifer L Willoughby, Christopher S Theile, Muthiah Manoharan, Leemor Joshua-Tor

Abstract readPublished Erratum
In one paragraph

Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Chemical Modifications in Nucleic Acid Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  4. Therapeutic siRNA: State-of-the-Art and Future Perspectives.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Elad ElkayamKeck Structural Biology Lab, Cold Spring Harbor, NY 11724, USA.
Rubina ParmarAlnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
Christopher R BrownAlnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
Jennifer L WilloughbyAlnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
Christopher S TheileAlnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
Muthiah ManoharanAlnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
Leemor Joshua-TorKeck Structural Biology Lab, Cold Spring Harbor, NY 11724, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID27986853
PMCPMC5416898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.